A Study to Assess S-217622 in Participants With Renal Impairment and Healthy Participants
A Phase 1, Open-label, Parallel-group Study to Assess the Pharmacokinetics, Safety, and Tolerability of S-217622 in Participants With Mild, Moderate, and Severe Renal Impairment and Healthy Control Participants
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Shionogi Clinical Trials Administrator Clinical Support Help Line
- Phone Number: 800-849-9707
- Email: Shionogiclintrials-admin@shionogi.co.jp
Study Locations
-
-
Florida
-
Miami, Florida, United States, 33014
- Clinical Pharmacology of Miami, LLC
-
Miami, Florida, United States, 33147
- Advanced Pharma Cr, Llc
-
Orlando, Florida, United States, 32809
- Orlando Clinical Research Center, Inc.
-
-
Minnesota
-
Saint Paul, Minnesota, United States, 55114
- Nucleus Network
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Body weight ≥ 50 kilograms (kg) and body mass index (BMI) within the range of ≥ 18.5 to < 38.0 kilogram-meter squared (kg/m^2) at the Screening visit
Participants With Renal Impairment
Participants that are not undergoing dialysis must have mild, moderate, or severe renal impairment based upon their Modification of Diet in Renal Disease (MDRD) creatinine clearance estimate (estimated glomerular filtration rate [eGFR]) calculated at the Screening visit:
- Mild renal impairment: 60 to 89 milliliters per minute (mL/min)/1.73 m^2
- Moderate renal impairment: 30 to 59 mL/min/1.73 m^2
- Severe renal impairment: No lower limit of eGFR, <30 mL/min
- A stable medication regimen is required, defined as not starting new drug(s) or changing dosage(s) within 14 days prior to administration of study intervention through the Follow-up/Early Termination visit.
Healthy Participants
- Participants with clinical laboratory tests within normal reference range for the laboratory, or abnormal but considered not clinically significant by the investigator. Renal function, calculated by MDRD, must be normal (ie, eGFR > 90 mL/min/1.73 m^2).
- Matched to each participant with moderate renal impairment with respect to sex, age (± 5 years), and BMI (± 10%).
Exclusion Criteria:
- Participants with life expectancy less than 3 months.
- History or presence of/significant history of or current cardiovascular, respiratory, hepatic, gastrointestinal (GI), endocrinological, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study intervention; or interfering with the interpretation of data.
- Current or chronic history of liver disease or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
- History of GI surgery including but not limited to gastric resection and/or intestinal resection that resulted in a clinically significant abnormality in GI function.
- Lymphoma, leukemia, or any malignancy within the past 5 years except for basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of metastatic disease for 3 years.
- Breast cancer within the past 10 years.
- Participant with poor venous access.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: S-217622: Group A
Participants with mild renal impairment will receive a single dose of S-217622 on Day 1, in a fasted state.
|
Tablet for oral administration
|
|
Experimental: S-217622: Group B
Participants with moderate renal impairment will receive a single dose of S-217622 on Day 1, in a fasted state.
|
Tablet for oral administration
|
|
Experimental: S-217622: Group C
Participants with severe renal impairment will receive a single dose of S-217622 on Day 1, in a fasted state.
|
Tablet for oral administration
|
|
Experimental: S-217622: Group D
Participants with normal renal function will receive a single dose of S-217622 on Day 1, in a fasted state.
|
Tablet for oral administration
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Maximum Observed Plasma Concentration (Cmax) of S-217622
Time Frame: 0 (predose) up to 336 hours postdose on Day 1 to Day 15
|
0 (predose) up to 336 hours postdose on Day 1 to Day 15
|
|
Time to Maximum Plasma Concentration (Tmax) of S-217622
Time Frame: 0 (predose) up to 336 hours postdose on Day 1 to Day 15
|
0 (predose) up to 336 hours postdose on Day 1 to Day 15
|
|
Area Under the Plasma Concentration-Time Curve (AUC) of S-217622
Time Frame: 0 (predose) up to 336 hours postdose on Day 1 to Day 15
|
0 (predose) up to 336 hours postdose on Day 1 to Day 15
|
|
Terminal Elimination Half-Life (t1/2,z) of S-217622
Time Frame: 0 (predose) up to 336 hours postdose on Day 1 to Day 15
|
0 (predose) up to 336 hours postdose on Day 1 to Day 15
|
|
Terminal Elimination Rate Constant (λz) of S-217622
Time Frame: 0 (predose) up to 336 hours postdose on Day 1 to Day 15
|
0 (predose) up to 336 hours postdose on Day 1 to Day 15
|
|
Mean Residence Time (MRT) of S-217622
Time Frame: 0 (predose) up to 336 hours postdose on Day 1 to Day 15
|
0 (predose) up to 336 hours postdose on Day 1 to Day 15
|
|
Apparent Total Clearance (CL/F) of S-217622
Time Frame: 0 (predose) up to 336 hours postdose on Day 1 to Day 15
|
0 (predose) up to 336 hours postdose on Day 1 to Day 15
|
|
Apparent Volume of Distribution (Vz/F) of S-217622
Time Frame: 0 (predose) up to 336 hours postdose on Day 1 to Day 15
|
0 (predose) up to 336 hours postdose on Day 1 to Day 15
|
|
Renal Clearance (CLR) of S-217622
Time Frame: 0 (predose) up to 336 hours postdose on Day 1 to Day 15
|
0 (predose) up to 336 hours postdose on Day 1 to Day 15
|
|
Fraction of Dose Excreted in Urine (Feu) of S-217622
Time Frame: 0 (predose) up to 336 hours postdose on Day 1 to Day 15
|
0 (predose) up to 336 hours postdose on Day 1 to Day 15
|
|
Fraction Unbound in Plasma (FU) of S217622
Time Frame: 0 (predose) up to 336 hours postdose on Day 1 to Day 15
|
0 (predose) up to 336 hours postdose on Day 1 to Day 15
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Number of Participants with Treatment-Emergent Adverse Events
Time Frame: Up to Day 21
|
Up to Day 21
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2128T1214
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.